Ulysses Neuroscience Secures €500k In Funding

The Irish Contract Research Organisation (CRO) Ulysses Neuroscience today announced that it has successfully raised €500K in investment from Enterprise Ireland and private investment company Growing Capital.

Since its foundation in June 2019, Ulysses Neuroscience has been providing the patient community and the global pharmaceutical industry with ground-breaking research services to advance knowledge and therapies for psychiatric diseases and rare neurological disorders.

Ulysses Neurosciences’ recent strategic move to the newly built Pioneer Group life sciences facilities in Cherrywood in Dublin has initiated a transformative phase of growth for the company, opening doors to a new industry network.  The company is currently hiring for preclinical and clinical neuroscience positions in the psychedelic, psychiatric and rare neurodevelopmental research space.

Dr. Massimiliano Bianchi, CEO of Ulysses Neuroscience said: “This raise of €500,000 in investment is an important milestone allowing us to expand our patient-centric and translational neuroscience research platforms. With a portfolio of globally based pharma clients and an annual revenue of over €1 million, we have been able to break through the CRO market and are helping a range of industries to bring their new therapies into clinical trials and subsequently onto the market.”

Dr Massimiliano Bianchi added: “The relocation to the Pioneer Group facilities in Cherrywood was driven by our vision to be the vanguard CRO in neuroscience drug discovery. Our new laboratories are fully operational and dedicated to performing and progressing the company biomarker and cell cultures operations.”

The company is also based onsite at Trinity College Dublin where a dedicated team of expert preclinical scientists are currently developing an electroencephalographic assay destined to be the next breakthrough model for exploring the use of psychedelics for the treatment of depression and the use of gene therapy for curing rare neurodevelopmental diseases. 

Gianni Matera, Founder, Growing Capital said: “We are delighted to support Ulysses Neuroscience in their pursuit to combat psychiatric diseases and rare neurological disorders, contributing to advancements in the pharmaceutical industry. We've been truly impressed by Ulysses' commitment to actively engaging patients in the research and drug development journey, ensuring their voices are not only heard but valued at every stage. It's gratifying to see this approach being acknowledged by the global pharmaceutical industry.”

Leo Clancy, CEO, Enterprise Ireland said, “Enterprise Ireland is delighted to support Ulysses Neuroscience and the important work they are doing in bringing ground-breaking treatment in the field of neurodevelopment to the market for the benefit of the patient community right across the world. With this funding the company plans to scale its operations, and continue to expand its market reach across the US, EU and Asian markets with a particular focus on expanding its clinical biomarker services. We look forward to working with the Ulysses Neuroscience team to realise their global ambition.”

ENDS

About Growing Capital: Growing Capital is an early-stage investment firm specializing in supporting startups with their roots in Ireland. To date, Growing Capital has supported over 30 Irish startups, including notable names such as Glofox, Flipdish, and Siren. Growing Capital typically directs its investments toward startups emerging from programs such as New Frontiers, Accelerator Programmes, Prep4Seed, and Commercialisation Fund.

About Ulysses Neuroscience Ltd.: Ulysses Neuroscience is a Trinity College Campus Company operating as a Contract Research Organization by providing preclinical and clinical research services to the global pharma industry. Ulysses Neuroscience offers unique patient-centric and translational research placing the patient community at the core of their relationship with the pharmaceutical industry. With offices and labs Located at the Pioneer Group life sciences facilities in Cherrywood and Trinity College Dublin, Ulysses Neuroscience has 15 employees and a portfolio of several clients worldwide with a strong presence in the US market.